Polymyositis

Researchers are studying pulmonary arterial hypertension (PAH), including its common subtypes idiopathic PAH (IPAH) and connective tissue disease-associated PAH (PAH-CTD). The study aims to develop pulmonary vascular biomarker signatures using hyperpolarized 129Xe MRI to differentiate these subtypes and to evaluate the ability of this imaging to monitor disease progression and treatment response over time. Additional assessments such as laboratory tests, echocardiography, and six-minute walk distance (6MWD) are also used to support these evaluations. The study is observational and enrolls 20 subjects divided into two groups: 10 with IPAH and 10 with PAH-CTD. Participants will undergo hyperpolarized 129Xe MRI and MR spectroscopy at baseline, 3 months, 6 months, and 12 months. Alongside imaging, data from standard clinical assessments including labs, echocardiography, and 6MWD will be collected at these same timepoints to track changes. Participants will be monitored for changes in pulmonary vascular remodeling, red blood cell oscillation amplitude, 6MWD, NTproBNP levels, and WHO functional class over one year. Safety is assessed by tracking adverse events, serious adverse events, withdrawals, and specific examinations such as electrocardiograms and vital signs. The total follow-up period for each participant is one year, with multiple scheduled evaluations to comprehensively assess disease status and response.

Researchers are evaluating an open-label, dose escalation study for patients with relapsed and refractory autoimmune diseases. The study focuses on a therapeutic biological product called TI-0032-III injection, which uses lipid nanoparticles to deliver circular RNA encoding the CD19 chimeric antigen receptor (CAR) targeting T cells. This treatment is intended for various difficult-to-treat B cell-related autoimmune diseases, including systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, idiopathic inflammatory myositis, and antiphospholipid syndrome. Participants will receive multiple doses of TI-0032-III injection infused into the body. This in vivo CD19-targeted CAR T cell therapy is being studied for safety and efficacy, with treatment delivered over a period involving dose escalation. The trial is an interventional Phase 1 study where the investigational injection is the main intervention. During the study, participants will be monitored for safety outcomes from the first dose up to 12 months. Researchers will also assess efficacy outcomes for the different autoimmune diseases up to 3 months after the first dose. Evaluations include clinical assessments and laboratory tests to measure treatment impact and safety. The total participant involvement will span at least one year to observe safety and disease response.

Researchers are studying the safety and effectiveness of YTS109 cells in adults aged 18 to 65 with relapsed or refractory autoimmune diseases, including Systemic Lupus Erythematosus (SLE) and related conditions such as Lupus Nephritis (LN), SLE-associated immune thrombocytopenia, Sjogren's Syndrome, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, and antiphospholipid syndrome. This phase 1, open-label study aims mainly to evaluate safety and also to examine how well YTS109 cells work and behave in the body. Participants will receive a single infusion of YTS109 cells, starting at a dose of 3×10⁶ STAR-T cells per kilogram of body weight. The dosing will follow a 3+3 escalation design to carefully adjust the dose. There is only one treatment group in this study. The infusion is a one-time procedure during the treatment period. During the study, participants will be closely monitored through regular assessments up to 52 weeks after treatment. Safety is tracked by observing adverse events and their severity. Effectiveness is assessed at multiple time points from 2 to 52 weeks. Blood tests will measure YTS109 cell levels, cytokine changes, and B cell recovery. Participants must agree to informed consent and follow-up visits to complete all evaluations throughout the study duration.

Researchers are evaluating the safety and potential effectiveness of YTS109 cells in adults aged 18 to 65 who have relapsed or refractory autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, and several others. This exploratory clinical trial aims to better understand how well YTS109 cells work and their safety when used with a lymphodepletion regimen. The study is conducted as a single-arm, open-label trial at a single center. Participants will receive one infusion of YTS109 cells at a dose of 1.5 million cells per kilogram of body weight. The study focuses on monitoring adverse events and assessing efficacy over various time points. The treatment is designed to target and reduce B cells to help manage autoimmune responses. The trial plans to enroll approximately 6 to 12 patients. During the study, participants will be closely monitored for safety and treatment effects at intervals including 2, 4, 8, 12, 24, and up to 52 weeks after treatment. Researchers will conduct blood tests to measure the levels of YTS109 cells, biomarker changes, and immune system responses. The primary outcomes are the type, severity, and frequency of any adverse effects, along with efficacy evaluations. The total observation period extends up to one year to thoroughly assess safety and response to treatment.

Researchers are evaluating the safety and effectiveness of YTS109 cells in adults aged 18 to 65 who have relapsed or refractory autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), SLE-associated immune thrombocytopenia (SLE-ITP), Sjogren's Syndrome, Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, and Antiphospholipid Syndrome (APS). This Phase 1, open-label trial will enroll about 18 patients to study safety, effectiveness, and how the YTS109 cells behave in the body. Participants will receive a single infusion of YTS109 cells starting at a dose of 3 million STAR-T cells per kilogram of body weight. The dose will be increased gradually using a 3+3 escalation method. The study focuses on observing adverse events and evaluating treatment response over several weeks. The trial is conducted by China Immunotech (Beijing) Biotechnology Co., Ltd. at the Institute of Hematology & Blood Diseases Hospital. During the study, patients will be monitored closely with assessments at 2, 4, 8, 12, 24, and up to 52 weeks after treatment. Researchers will track the types, severity, and frequency of any adverse events, measure drug levels in the blood, evaluate immune system responses, and assess disease activity. This detailed monitoring includes laboratory tests and clinical evaluations to ensure patient safety and to understand how the therapy affects the autoimmune conditions over time.

This research focuses on people who have previously been treated with KYV-101, an autologous CAR T cell therapy, to monitor long-term safety and persistence of the treatment. It aims to collect information about delayed side effects and ongoing presence of the gene-modified cells in participants who received at least one infusion of KYV-101 in earlier clinical trials sponsored by Kyverna Therapeutics. Participants in this observational study will continue to be followed for up to 15 years after their initial KYV-101 treatment. The study will track various health outcomes including treatment-related adverse events, new or returning malignancies, neurological and autoimmune conditions, blood disorders, infections, and specific laboratory tests related to the therapy. For some participants with certain conditions, additional measures like medication use and functional assessments will be monitored for shorter periods. Throughout the study, participants will undergo regular health evaluations, lab tests, and questionnaires to assess the long-term effects of KYV-101. Researchers will collect data on safety events and laboratory markers up to 15 years, with some specific tests monitored up to 5 years. The overall goal is to better understand the long-term impact and safety profile of the gene-modified therapy in people treated previously.

Researchers are studying the safety, tolerability, how the body processes, and immune response to XmAb657 in healthy adults and adults with autoimmune diseases such as Idiopathic Inflammatory Myopathies, Systemic Sclerosis, and Sjogren's Disease. This is a Phase 1, first-in-human, open-label clinical trial evaluating the effects of XmAb657 given by injection under the skin. The study aims to better understand the potential effects of XmAb657 in these populations. Participants will receive XmAb657 as a subcutaneous injection in a dose-escalation format. The study includes healthy adults and adults diagnosed with specific autoimmune diseases based on established classification criteria. The treatment is administered under medical supervision, and dosing levels may increase over time to monitor safety and immune responses. During the study, participants will be monitored for any side effects or adverse reactions, including serious or treatment-emergent events, through week 52. Blood samples will be collected to measure the levels of XmAb657 and assess its effects on the immune system. The study involves regular visits for safety assessments and pharmacokinetic and pharmacodynamic evaluations. Participants may be involved for up to a year to ensure thorough monitoring.

Researchers are evaluating anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR-T cell therapy, in adults with generalized myasthenia gravis (GMG) classified as MGFA Grade 2 to 4a. This Phase 1 open-label, multi-center study aims to assess the safety, tolerability, and preliminary efficacy of anito-cel in patients who require immunosuppressive therapy as determined by their neurologist. The study focuses on identifying dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), and selecting the recommended Phase 2 dose (RP2D) for treatment. The study includes sequential phases: screening, enrollment with leukapheresis to collect cells, pretreatment with a standard lymphodepletion chemotherapy regimen for 5 days, and a single intravenous infusion of anito-cel cells. Optional bridging therapy may be given while the CAR-T cells are prepared. Following infusion, participants will be closely monitored for safety and efficacy outcomes over time. Participants will undergo safety monitoring for at least 28 days after infusion, with safety data collected throughout the study duration of up to 24 months. Clinical effects will be evaluated using measures including the Myasthenia Gravis Activities of Daily Living (MG ADL) score, Quantitative Myasthenia Gravis (QMG) score, and Myasthenia Gravis Composite (MGC) scale. Additionally, blood tests will monitor autoantibody levels and pharmacokinetics of the therapy. This comprehensive follow-up ensures careful assessment of treatment impact and participant health.

Researchers are evaluating NKX019, an investigational allogeneic CAR NK cell therapy targeting CD19, in adults with various autoimmune diseases. This Phase 1/2 open-label, multi-center study aims to assess the safety and tolerability of NKX019, as well as preliminary efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity. The study includes participants with systemic sclerosis, idiopathic inflammatory myopathies, ANCA-associated vasculitis, and rheumatoid arthritis. Participants undergo a dose escalation phase following a "3+3" design to find the recommended dose for further study. Treatment cycles include lymphodepletion with fludarabine and cyclophosphamide, or cyclophosphamide alone for those with low blood cell counts, followed by three doses of NKX019. The study will expand to enroll more participants across different autoimmune conditions based on dose findings. During the study, participants will be monitored closely for adverse events and dose-limiting toxicities, especially within the first 28 days after the first NKX019 dose. Follow-up evaluations include laboratory tests, assessments of lung and muscle function, and immune response tracking for up to two years post-infusion. Researchers will also assess the impact of treatment on background therapies and measure drug levels and immune responses over time.

Researchers are studying the safety and effectiveness of a single dose of nexiguran ziclumeran (NTLA-2001) compared to a placebo in people with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This phase 3, multinational, randomized, double-blind, placebo-controlled trial involves about 60 participants with this nerve disease and genetic condition affecting the peripheral nervous system. Participants will be randomly assigned to receive a single intravenous infusion of either nexiguran ziclumeran 55 mg or a placebo of normal saline. To give everyone a chance to receive the study drug, participants may switch to the other treatment group at either 12 or 18 months, depending on specific study criteria. The study is designed to compare the effects of the drug and placebo over time. During the study, participants will be monitored for nerve function using the Modified Neuropathy Impairment Score +7 (mNIS+7) over 18 months and blood levels of serum transthyretin at 29 days and 18 months. Quality of life, body mass index, and other health measures will also be evaluated. The study includes careful safety monitoring and will last up to 18 months with ongoing assessments to track participants' nerve health and overall well-being.